Search results
Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise
Investor's Business Daily· 6 days agoThe company sells genetic tests to detect cancer, as well as for women's and organ health. The March...
Natera Inc (NTRA) Surpasses Analyst Revenue Forecasts in Q1 2024
GuruFocus.com via Yahoo Finance· 6 days ago23) per diluted share, in Q1 2023. The company's operating expenses were $282.9...
Risk of ‘genetic discrimination’ by insurance companies is ruining people’s trust in vital medical...
The Conversation· 9 hours agoShould you be denied life insurance or have to pay extra if you have a genetic risk for certain diseases? Should insurance companies even have access to your genetic ...
Know Your Risk for Blood Clots Before Taking Birth Control
Quad-City Times· 3 days agoSelecting the right birth control method is pivotal, say experts, who point to research that shows...
Researchers show genetic variant common among Black Americans contributes to large cardiovascular...
Medical Xpress· 4 days agoA genetic variant carried by 3-4 percent of self-identified Black Americans increases the risk for...
Natera (NASDAQ:NTRA) Price Target Increased to $125.00 by Analysts at BTIG Research
ETF DAILY NEWS· 6 hours agoNatera (NASDAQ:NTRA – Free Report) had its price target increased by BTIG Research from $100.00 to $125.00 in a report released on Monday, Benzinga reports. NTRA has been the subject of a number ...
Organic Farming Leads To Adaptations In The Genetic Material In Plants
FoodOnline· 3 days agoPlants adapt genetically over time to the special conditions of organic farming. This has been demonstrated in a long-term study conducted at the University of Bonn. The researchers planted ...
Sweetgreen, Natera rise; Collegium Pharmaceutical, Akamai fall, 5/10/2024
Associated Press Finance via Yahoo Finance· 6 days agoNatera Inc., up $9.74 to $105.29. The genetic testing company raised its revenue forecast for the year. Progyny Inc., down $4.97 to $27.53. The provider of fertility...35.91 ...
QIAGEN (QGEN) Wins FDA Nod for QIAstat-Dx Respiratory Panel Plus
Zacks via Yahoo Finance· 2 days agoHims & Hers Heath stock has increased 19.7% in the past year. Earnings estimates for the company...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for...
Morningstar· 2 days agoTOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...